Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel

Clinical trials have demonstrated the efficacy and safety of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM); however, prospective real‐world data are limited. This real‐world, prospective, observational study evaluated carfilzomib use, effectiveness and safety in adults wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Leleu, Xavier, Katodritou, Eirini, Kuehr, Thomas, Terpos, Evangelos, Caers, Jo, Zambello, Renato, Brescianini, Alessandra, Liang, Tony, Wetten, Sally, Badelita, Sorina N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematologic Malignancy ‐ Plasma Cell
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928790/
https://www.ncbi.nlm.nih.gov/pubmed/36819146
http://dx.doi.org/10.1002/jha2.595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928790/
https://www.ncbi.nlm.nih.gov/pubmed/36819146
http://dx.doi.org/10.1002/jha2.595

Ejemplares similares